Management Options
Treatment options for ATTR aim to stabilize the TTR protein, reduce amyloid deposits and manage symptoms. Key treatments include:
hATTR
Approved by Health Canada for the treatment of hereditary ATTR-polyneuropathy, eplontersen Is a ligand-conjugated antisense (LICA) medicine designed to reduce the production of transthyretin, or TTR protein. Eplontersen is the first and only therapy that can be self-administered at home via an auto-injector.
Approved by Health Canada hATTR for polyneuropathy
RNA interference (RNAi) therapies that reduce TTR protein production by targeting TTR mRNA. These treatments are particularly effective, and thus only indicated in Canada, for hereditary ATTR with polyneuropathy.
Approved by Health Canada
RNA interference (RNAi) therapies that reduce TTR protein production by targeting TTR mRNA. These treatments are particularly effective, and thus only indicated in Canada, for hereditary ATTR with polyneuropathy. Administered by Health Care Professional once per 3 months.
Considered for hereditary ATTR, especially in younger patients, as it removes the primary source of mutant TTR production. However, it is not suitable for wild-type ATTR.
Other
Wild-type ATTR
Vyndaqel & Vyndamax are approved medications by Health Canada for cardiomyopathy.
- Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are both used to treat the wild-type and hereditary forms of transthyretin amyloid cardiomyopathy (ATTR-CM).
- Vyndaqel and Vyndamax contain different forms of tafamidis. Both versions work the same way in the body. The Vyndamax dosage is one pill daily. But Vyndaqel contains a smaller amount of tafamidis, so you need to take four pills instead.
hATTR
RNA interference (RNAi) therapies that reduce TTR protein production by targeting TTR mRNA. These treatments are particularly effective, and thus only indicated in Canada, for hereditary ATTR with polyneuropathy.
Approved by Health Canada for the treatment of hereditary ATTR-polyneuropathy, eplontersen Is a ligand-conjugated antisense (LICA) medicine designed to reduce the production of transthyretin, or TTR protein. Eplontersen is the first and only therapy that can be self-administered at home via an auto-injector.
Considered for hereditary ATTR, especially in younger patients, as it removes the primary source of mutant TTR production. However, it is not suitable for wild-type ATTR.
RNA interference (RNAi) therapies that reduce TTR protein production by targeting TTR mRNA. These treatments are particularly effective, and thus only indicated in Canada, for hereditary ATTR with polyneuropathy.